David Mauro
Directeur Technique/Scientifique/R&D chez RECURSION PHARMACEUTICALS, INC.
Fortune : 2 M $ au 31/05/2024
Postes actifs de David Mauro
Sociétés | Poste | Début | Fin |
---|---|---|---|
RECURSION PHARMACEUTICALS, INC. | Directeur Technique/Scientifique/R&D | 01/06/2023 | - |
Historique de carrière de David Mauro
Anciens postes connus de David Mauro
Sociétés | Poste | Début | Fin |
---|---|---|---|
CODIAK BIOSCIENCES | Directeur Technique/Scientifique/R&D | 02/05/2022 | 07/04/2023 |
CHECKMATE PHARMACEUTICALS, INC. | Directeur Technique/Scientifique/R&D | 20/04/2016 | 15/10/2019 |
AYALA PHARMACEUTICALS, INC. | Directeur Technique/Scientifique/R&D | 23/10/2014 | 01/02/2016 |
MERCK & CO., INC. | Directeur/Membre du Conseil | 01/01/2007 | 01/01/2014 |
BRISTOL-MYERS SQUIBB COMPANY | Directeur/Membre du Conseil | - | - |
PRELUDE THERAPEUTICS INCORPORATED | Directeur Technique/Scientifique/R&D | 01/05/2019 | - |
Formation de David Mauro
Cornell University | Undergraduate Degree |
Temple University School of Medicine | Doctorate Degree |
Statistiques
Internationale
Etats-Unis | 10 |
Opérationnelle
Chief Tech/Sci/R&D Officer | 5 |
Director/Board Member | 2 |
Undergraduate Degree | 1 |
Sectorielle
Health Technology | 8 |
Consumer Services | 3 |
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Sociétés liées
Sociétés cotées | 4 |
---|---|
PRELUDE THERAPEUTICS INCORPORATED | Health Technology |
MERCK & CO., INC. | Health Technology |
BRISTOL-MYERS SQUIBB COMPANY | Health Technology |
RECURSION PHARMACEUTICALS, INC. | Health Technology |
Entreprise privées | 3 |
---|---|
Advaxis, Inc.
Advaxis, Inc. Pharmaceuticals: MajorHealth Technology Advaxis, Inc. is a biotechnology company, which engages in the discovery, development and commercialization of cancer immunotherapies. It manages platform technology that utilizes live attenuated Listeria monocytogenes bioengineered to secrete antigen or adjuvant fusion proteins. The firm has four franchises in various stages of clinical and pre-clinical development, namely: HPV-associated cancers, prostate cancer, neoantigen therapy and hotspot mutation therapy. The company was founded on June 5, 1987 and is headquartered in Princeton, NJ. | Health Technology |
Checkmate Pharmaceuticals, Inc.
Checkmate Pharmaceuticals, Inc. BiotechnologyHealth Technology Checkmate Pharmaceuticals, Inc. is a clinical-stage biotechnology company, which engages in developing and commercializing proprietary technology to harness the power of the immune system to combat cancer. The firm's product candidate, vidutolimod is a differentiated TLR9 agonist delivered as a biologic virus-like particle designed to trigger the body's innate immune system to attack tumors in combination with other therapies. The company was founded by Arthur M. Krieg and Chuck Yo in July 2015 and is headquartered in Cambridge, MA. | Health Technology |
Codiak BioSciences, Inc.
Codiak BioSciences, Inc. Pharmaceuticals: MajorHealth Technology Codiak BioSciences, Inc. engages in the development and manufacturing of exosomes. It engages in harnessing exosomes, therapeutic applications, diagnostic applications, and proprietary production. The firm develops engEx Platform, a proprietary and versatile exosome engineering and manufacturing platform, to expand upon the innate properties of exosomes to design novel exosome therapeutics. Codiak BioSciences was founded by Douglas E. William, Raghu Kalluri, and Eric S. Lander in 2015 and is headquartered in Cambridge, MA. | Health Technology |
- Bourse
- Insiders
- David Mauro
- Expérience